The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody
conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a …

Antibody–drug conjugates (ADCs) combine the specificity of antibodies with the potency of
small molecules to create targeted drugs. Despite the simplicity of this concept, generation of …

Antibody drug conjugates (ADCs) have emerged as an important pharmaceutical class of
drugs designed to harness the specificity of antibodies with the potency of small molecule …

The unique class of heavy chain–only antibodies, present in Camelidae, can be shrunk to
just the variable region of the heavy chain to yield VHHs, also called nanobodies. About one …

Methods for site-specific modification of proteins should be quantitative and versatile with
respect to the nature and size of the biological or chemical targets involved. They should …

The development of therapeutic cancer vaccines as a means to generate immune reactivity
against tumors has been explored since the early discovery of tumor-specific antigens by …

Breaking and forming peptidyl bonds are fundamental biochemical reactions in protein
chemistry. Unlike proteases that are abundantly available, fast-acting ligases are rare …

Antibody drug conjugates (ADCs) have recently been proven to be highly potent anti-tumor
drugs, typically exceeding the efficacy of conventional monoclonal antibodies (mAbs). ADCs …

Sortase‐mediated hydrazinolysis of proteins with hydrazine or its derivatives was developed
for the production of recombinant protein hydrazides. This process provides an alternative …

Monoclonal antibodies (mAbs) and their derivatives are currently the fastest growing class of
therapeutics. Even if naked antibodies have proven their value as successful …